Quadratus Lumborum Block for Total Hip Arthroplasty

Pain, Postoperative Clinical Trial

Official title:

Quadratus Lumborum (QL) Nerve Block for Patients Undergoing Primary Total Hip Arthroplasty (THA)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05247255
• Other study ID #: 21-001850
• Status: Recruiting
• Phase: Early Phase 1
• Start date: March 29, 2022
• Est. completion date: March 2025

Study information

• Verified date: December 2023
• Source: University of California, Los Angeles
• Contact: Jennifer Scovotti, MA
• Phone: 310-206-4484
• Email: jscovotti[@]mednet.ucla.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The quadratus lumborum (QL) block is a fascial plane block that has been described to provide analgesia from T7-L3 dermatomes. The investigators aim to evaluate the efficacy of QL blocks in patients undergoing primary total hip arthroplasty (THA).

Description:

Investigators will enroll subjects planned for primary THA and allocate them into receiving a QL block with either saline or ropivacaine. Primary outcome will be pain scores over the first 48 hours after surgery.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 80
• Est. completion date: March 2025
• Est. primary completion date: February 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Adult subjects undergoing elective primary total hip arthroplasty

Exclusion Criteria:

• patients age < 18,

• documented allergy to local anesthetic

• presence of peripheral neuropathy

• patients with current long term opioid use defined as receiving an opioid on most days in a 90 day period

• patients with a contraindication to spinal and regional anesthesia such as coagulopathy or infection at the site of the regional technique.

Related Conditions & MeSH terms

• Pain, Postoperative

Intervention

Drug:
• Active Comparator
QL block with 0.25% ropivacaine
• Placebo Comparator
QL block with saline

Locations

Country	Name	City	State
United States	UCLA Medical Center, Santa Monica	Santa Monica	California

Sponsors (1)

Lead Sponsor	Collaborator
University of California, Los Angeles

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Pain score	Pain scores will be assessed over 48hrs postop using the visual analog score	Up to 48 hrs post op
Secondary	Opioid usage	Total morphine-equivalent will be calculated at 0-24hrs and 24-48hrs postop.	Up to 48 hrs post op
Secondary	Time to first stand	The period between the end of surgery and the patient's first successful attempt at standing, with or without the assistance of devices (i.e. walker, cane) or staff assistance.	Up to 1 week post surgery
Secondary	Time to first ambulation	Time to first ambulation of 50 feet or more, with or without the help of assist devices (i.e. walker, cane) or staff assistance.	Up to 1 week post surgery
Secondary	Ambulation distance	This data point will be measured in feet and will be determined by the distance ambulated during the patient's first ambulation attempt after surgery, regardless of the length of ambulation (This distance will be counted regardless of whether the patient reaches the 50 feet requirement to be counted as the "time to first ambulation).	Up to 1 week post surgery
Secondary	Length of hospital stay	Number of days in the hospital from postoperative day 0 to discharge	Until discharge from hospital, up to 1 week post surgery
Secondary	Patient satisfaction	Patient satisfaction score will be assessed on day of discharge as measured by a 5-point scale with 1 = terrible, 2 = poor, 3 = satisfactory, 4 = good, and 5 = excellent.	Until day of discharge from the hospital, up to 1 week post surgery